AKEBIA THERAPEUTICS, INC. (AKBA) Current Ratio
- Current ratio · latest quarter: Value 1.43×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.43× | Current assets / current liabilities. $229.55M ÷ $160.87M ≈ 1.43× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 229.55M USD | Assets, Current |
| Current obligations | 160.87M USD | Liabilities, Current |
| Cash and equivalents | 155.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 53.51M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 13.02M USD | Inventory, Net |
| Payables | 9.42M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 24.81M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $229.55M | $160.87M | $155.55M | (m) | $53.51M | $13.02M | $9.42M | $24.81M | 1.43× |
| 2026-03-31 | $243.48M | $173.88M | $162.64M | (m) | $62.54M | $13.00M | $8.39M | $12.49M | 1.40× |
| 2025-12-31 | $252.96M | $162.94M | $184.84M | (m) | $47.03M | $15.61M | $21.18M | $0.00 | 1.55× |
| 2025-09-30 | $258.34M | $133.38M | $166.44M | (m) | $66.22M | $18.64M | $10.09M | (m) | 1.94× |
| 2025-06-30 | $234.66M | $118.72M | $137.31M | (m) | $72.81M | $16.71M | $11.55M | (m) | 1.98× |
| 2025-03-31 | $203.78M | $91.23M | $113.37M | (m) | $61.54M | $19.73M | $12.66M | (m) | 2.23× |
| 2024-12-31 | $113.83M | $80.91M | $51.87M | (m) | $34.37M | $16.24M | $15.18M | (m) | 1.41× |
| 2024-09-30 | $100.12M | $65.71M | $34.02M | (m) | $32.17M | $20.49M | $13.49M | $0.00 | 1.52× |
| 2024-06-30 | $112.10M | $107.30M | $39.50M | (m) | $29.77M | $23.87M | $10.11M | $0.00 | 1.04× |
| 2024-03-31 | $112.94M | $66.49M | $41.96M | (m) | $26.62M | $25.53M | $11.88M | $0.00 | 1.70× |
| 2023-12-31 | $118.15M | $99.87M | $42.92M | (m) | $39.29M | $15.69M | $14.63M | $17.50M | 1.18× |
| 2023-09-30 | $109.60M | $79.70M | $46.53M | (m) | $22.59M | $18.44M | $9.04M | $8.00M | 1.38× |
| 2023-06-30 | $118.45M | $92.18M | $53.57M | (m) | $19.57M | $20.91M | $11.78M | $24.00M | 1.28× |
| 2023-03-31 | $120.80M | $87.66M | (m) | (m) | $18.73M | $20.41M | (m) | (m) | 1.38× |
| 2022-12-31 | $185.18M | $129.54M | $90.47M | (m) | $40.28M | $21.57M | $18.02M | $32.00M | 1.43× |
| 2022-09-30 | $242.21M | $193.13M | (m) | (m) | $23.27M | $45.24M | (m) | (m) | 1.25× |
| 2022-06-30 | $308.25M | $237.40M | (m) | (m) | $82.00M | $40.23M | (m) | (m) | 1.30× |
| 2022-03-31 | $305.14M | $258.50M | (m) | (m) | $65.36M | $41.10M | (m) | (m) | 1.18× |
| 2021-12-31 | $271.15M | $261.05M | $149.80M | (m) | $51.58M | $36.63M | $33.59M | $97.54M | 1.04× |
| 2021-09-30 | $330.08M | $189.21M | $207.20M | (m) | $49.69M | $33.69M | $28.81M | (m) | 1.74× |
| 2021-06-30 | $331.08M | $165.59M | $246.99M | (m) | $35.01M | $37.90M | $41.98M | (m) | 2.00× |
| 2021-03-31 | $365.02M | $172.68M | $252.76M | (m) | $35.23M | $44.81M | $30.54M | (m) | 2.11× |
| 2020-12-31 | $371.44M | $187.15M | $228.70M | (m) | $26.85M | $61.02M | $41.31M | $0.00 | 1.98× |
| 2020-09-30 | $391.00M | $181.46M | $169.29M | (m) | $24.47M | $88.24M | $40.40M | (m) | 2.15× |
| 2020-06-30 | $449.10M | $195.77M | $245.41M | (m) | $39.12M | $104.60M | $29.41M | (m) | 2.29× |
| 2020-03-31 | $340.76M | $214.15M | $115.37M | (m) | $104.87M | $111.85M | $54.38M | (m) | 1.59× |
| 2019-12-31 | $309.53M | $208.12M | $147.45M | (m) | $38.86M | $116.35M | $39.22M | (m) | 1.49× |
| 2019-09-30 | $299.01M | $223.15M | $122.89M | $22.73M | $29.65M | $115.99M | $64.36M | (m) | 1.34× |
| 2019-06-30 | $316.40M | $185.62M | $87.21M | $49.55M | $28.89M | $122.14M | $19.32M | (m) | 1.70× |
| 2019-03-31 | $347.23M | $202.61M | $62.74M | $105.30M | $48.44M | $115.21M | $15.23M | (m) | 1.71× |
| 2018-12-31 | $468.27M | $265.69M | $104.64M | (m) | $16.67M | $114.25M | $42.80M | $15.00M | 1.76× |
| 2018-09-30 | $397.53M | $177.40M | $162.43M | $212.72M | $688.00K | (m) | $12.68M | (m) | 2.24× |
| 2018-06-30 | $407.42M | $164.42M | $163.53M | $206.42M | $132.00K | (m) | $4.79M | (m) | 2.48× |
| 2018-03-31 | $436.98M | $151.42M | $158.17M | $191.26M | $35.85M | (m) | $17.88M | (m) | 2.89× |
| 2017-12-31 | $358.36M | $141.11M | $70.16M | (m) | $34.22M | (m) | $7.00M | (m) | 2.54× |
| 2017-09-30 | $333.94M | $151.36M | $89.60M | $217.43M | (m) | (m) | $8.71M | (m) | 2.21× |
| 2017-06-30 | $332.39M | $181.59M | $125.39M | $191.18M | (m) | (m) | $10.21M | (m) | 1.83× |
| 2017-03-31 | $255.05M | $133.46M | $87.25M | $151.85M | (m) | (m) | $15.08M | (m) | 1.91× |
| 2016-12-31 | $296.32M | $114.27M | $187.34M | $73.01M | $33.82M | (m) | $2.04M | (m) | 2.59× |
| 2016-09-30 | $165.15M | $26.14M | $65.83M | $78.82M | (m) | (m) | $8.52M | (m) | 6.32× |
| 2016-06-30 | $192.52M | $20.93M | $46.18M | $114.89M | (m) | (m) | $5.14M | (m) | 9.20× |
| 2016-03-31 | $219.53M | $13.41M | $43.44M | $122.98M | (m) | (m) | $2.42M | (m) | 16.37× |
| 2015-12-31 | $141.02M | $11.87M | $49.78M | $88.68M | (m) | (m) | $2.31M | (m) | 11.88× |
| 2015-09-30 | $158.80M | $14.17M | $66.71M | $39.78M | $14.00K | (m) | $5.27M | (m) | 11.21× |
| 2015-06-30 | $154.96M | $5.90M | $76.25M | $37.78M | $48.00K | (m) | $2.41M | (m) | 26.25× |
| 2015-03-31 | $102.69M | $8.84M | $27.89M | $39.34M | $74.00K | (m) | $4.33M | (m) | 11.62× |
| 2014-12-31 | $110.48M | $6.88M | $32.78M | $76.14M | (m) | (m) | $2.02M | (m) | 16.05× |
| 2014-09-30 | $119.84M | $6.52M | $49.67M | $27.33M | $57.00K | (m) | $3.03M | (m) | 18.37× |
| 2014-06-30 | $126.05M | $4.77M | $95.39M | $9.89M | $113.95K | (m) | $1.49M | (m) | 26.43× |
| 2014-03-31 | $133.74M | $6.12M | $126.32M | (m) | $119.39K | (m) | $2.08M | (m) | 21.84× |
| 2013-12-31 | $33.43M | $3.90M | $21.22M | $11.34M | $135.00K | (m) | $714.00K | (m) | 8.57× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |